Vical incorporated has initiated a human Phase 1 study of an investigational method of delivering interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma.
- Mechanism
- Curator reviewed
Intravenous delivery of IL-2 protein is approved as a treatment for metastatic melanoma, but frequently causes severe systemic toxicities. The novel treatment approach being studied in this trial involves direct injection into a tumor lesion of plasmid DNA (pDNA) encoding IL-2 followed by electroporation, the local application of electrical pulses designed to enhance the uptake of the pDNA into tumor cells. The pDNA is designed to cause cells within the tumor to produce high levels of IL-2 protein locally and stimulate the immune system to attack the tumor without the associated systemic toxicities.
- Primary indication
- Investigated for use/treatment in melanoma.Curator reviewed
What you can answer from here — as of April 02, 2025
Which companies are running trials of IL-2 pDNA, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account